image_alt_text
2

Kathleen M. Schmainda, Ph.D.

AIMBE College of Fellows Class of 2016
For the development of biologically relevant and clinically actionable MRI metrics of the vascular and invasive status of brain tumors

Innovative Therapy that “Tricks” and Destroys Cancer Cells Advances to Clinical Trial

Via PR Newswire | April 8, 2022

A novel therapy studied at the Medical College of Wisconsin (MCW) Cancer Center has led to a clinical trial for the treatment of glioblastoma, a rare and aggressive form of brain cancer, yet the most common primary brain tumor in adults.

Despite decades of research globally, only incremental gains have been made to extend or enhance quality of life for patients with glioblastoma. Treatment options are limited and typically include a combination of surgery, radiation therapy, and chemotherapy. Now, a new clinical study open at Froedtert & the Medical College of Wisconsin will evaluate an alternative treatment that is administered orally… Continue reading.

Kathleen M. Schmainda, Ph.D. To be Inducted into Medical and Biological Engineering Elite

Via AIMBE | January 20, 2016

WASHINGTON, D.C.— The American Institute for Medical and Biological Engineering (AIMBE) has announced the pending induction of Kathleen M. Schmainda, Ph.D., Professor, Radiology, Medical College of Wisconsin, to its College of Fellows. Dr. Schmainda was nominated, reviewed, and elected by peers and members of the College of Fellows For the development of biologically relevant and clinically actionable MRI metrics of the vascular and invasive status of brain tumors.